TY - JOUR
T1 - Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM)
T2 - A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities
AU - Harden, Avis
AU - Ragoonanan, Dristhi
AU - Anildes-Gubman, Daryl
AU - McCall, David
AU - Faltus, Kathleen
AU - Featherston, Sarah
AU - Shoberu, Basirat
AU - Moffet, Jerelyn R.
AU - Petropoulos, Demetrios
AU - Khazal, Sajad J.
AU - Razvi, Shehla
AU - Mahadeo, Kris M.
AU - Tewari, Priti
N1 - Funding Information:
We sincerely thank the following for their invaluable contribution to this manuscript: Ms. Brandy Adams and Marisol Gonzalez for their administrative support. Joan O'Hanlon Curry, MS, RN, CPNP, CPON; the Association of Pediatric Hematology and Oncology Nurses (APHON); the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network; the Teaching, Inter-professional and Simulation (TIPS) Education Center; and the CARTOX Program at the University of Texas at MD Anderson Cancer Center are acknowledged for their assistance.
Publisher Copyright:
© Copyright © 2020 Harden, Ragoonanan, Anildes-Gubman, McCall, Faltus, Featherston, Shoberu, Moffet, Petropoulos, Khazal, Razvi, Mahadeo and Tewari.
PY - 2020/8/5
Y1 - 2020/8/5
N2 - Chimeric antigen receptor (CAR) therapies such as tisagenlecleucel, indicated for children and young adults with relapsed and/or refractory CD19+ acute lymphoblastic leukemia (ALL), have been associated with striking treatment outcomes and overall survival. Yet, they are also associated with unique and potentially life-threatening complications. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS) are generally reversible complications of CAR therapies, but many patients may require critical care support especially if they are not promptly recognized and appropriately managed by frontline healthcare staff. As CAR therapies become more widely available, it is important that inter-professional staff members be aware of general principles regarding diagnosis and management. We hypothesized that an inter-professional education (IPE) simulation-based education intervention (CAR-TEAM) would improve knowledge base and confidence regarding complications of CAR therapies among inter-professional staff. Here, we demonstrate that following CAR-TEAM training, >90% of participants demonstrated knowledge proficiency and confidence in the IPE content area. CAR-TEAM training may serve as an important tool to establish initial and continued competency among sites introducing CAR therapies.
AB - Chimeric antigen receptor (CAR) therapies such as tisagenlecleucel, indicated for children and young adults with relapsed and/or refractory CD19+ acute lymphoblastic leukemia (ALL), have been associated with striking treatment outcomes and overall survival. Yet, they are also associated with unique and potentially life-threatening complications. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS) are generally reversible complications of CAR therapies, but many patients may require critical care support especially if they are not promptly recognized and appropriately managed by frontline healthcare staff. As CAR therapies become more widely available, it is important that inter-professional staff members be aware of general principles regarding diagnosis and management. We hypothesized that an inter-professional education (IPE) simulation-based education intervention (CAR-TEAM) would improve knowledge base and confidence regarding complications of CAR therapies among inter-professional staff. Here, we demonstrate that following CAR-TEAM training, >90% of participants demonstrated knowledge proficiency and confidence in the IPE content area. CAR-TEAM training may serve as an important tool to establish initial and continued competency among sites introducing CAR therapies.
KW - cytokine release syndrome (CRS)
KW - education
KW - immune effector cell-associated neurotoxicity (ICANS)
KW - inter-professional
KW - simulation-based
UR - http://www.scopus.com/inward/record.url?scp=85089806193&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089806193&partnerID=8YFLogxK
U2 - 10.3389/fonc.2020.01227
DO - 10.3389/fonc.2020.01227
M3 - Article
C2 - 32850365
AN - SCOPUS:85089806193
SN - 2234-943X
VL - 10
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 1227
ER -